The Lowdown on Cancer focuses on the impact of cancer on lives and on the things that give us hope. From the pain of learning you have cancer to innovative new treatments offered by the best and brightest, we’ll give you the Lowdown.
Yes, cancer sucks. But you are not alone. And we are not without hope!
Supporting cancer research is good. It's important. It funds scientists and labs and countless "EUREKA!" moments in the lab that might help cancer patients. But research isn't the wole story. In fact, it's a very small part of the story. What happens...
This year we are thankful for how far we've come. From our first investment to meeting more than a dozen innovators, and of course to learning about so many real people who've been impacted by cancer. Thank you for being a part of the journey. There is so...
Over the past weeks, we've introduced four additional innovators at the forefront of cancer: ONCO-LIQ - Cancer detection through routine blood testing TELEXOS - Improved cancer diagnostics through detection of circulating tumor cells in blood BETAGLUE -...
"We know that 50% of humans will have cancer at some time in their life." Well if that wasn't enough of a gut punch, wait for this statistic: Of those people with cancer, 50% will be diagnosed with advanced tumors. Which means treatment options may be...
Meet Telexos GmbH. Telexos develops products for the clinical cancer research market and for the personalized cancer diagnostics market. Their focus is on the detection and analysis of rare cells in the blood, in particular circulating tumor cells (CTCs)...
We scoured the globe to bring you this latest innovator! Meet BetaGlue Technologies, a global team of medical industry professionals developing a new technology in the loco-regional therapy of solid tumors. And while it may sound like the stuff of sci-fi...
1 in 5 Americans are at increased risk for hereditary or genetic risk of developing cancer. But most don't even realize it. Sure, we've all filled out those family history forms at the doctor's office. But how well informed were you about your family...
In 2021, an estimated 323,840 new cases of breast cancer are expected to be diagnosed in men and women in the U.S. alone. Approximately 43% of those cases will choose surgical breast reconstruction. Although nipple-sparing surgeries (leaving the...
Our latest innovator bucks the trend, as a "for-profit, social impact, health tech startup." The cancer journey is overwhelming for patients and caregivers. And while many people struggle to advocate for themselves and their loved ones after a cancer...
We've shared some gut-wrenching stories as part of "Save Second Base," our series on breast cancer. But now we share some glimmers of hope. CANCER FUND is more than hope. Through investing in innovation, we bring diagnostics, treatments, and solutions to...
Kent was traveling a lot for work, enjoying life with his wife, Bonnie, on the weekends. “Life was running smooth.” Then Kent discovered a lump in his breast, by his nipple. “Like any red-blooded American male, I ignored it!” It wasn’t until he noticed...
When it comes to cancer advocacy and innovation, we aren't just talking about treatments. At CANCER FUND, our primary goal is to improve the lives of cancer patients, survivors, and at-risk populations. People like Robyn. Robyn had cancer in her 20's and...
We recently met Delia, who was diagnosed with Breast Cancer at age 28. Now we bring you Bret’s story. Bret Miller was a seemingly normal 24-year-old, athletic, healthy guy, with a mass in his right breast since the age of 17. “The first time I...
Experts agree that mammograms are the best screening test for women at average risk for breast cancer. But they don't all agree on the age at which a woman should start or whether she should be screened every year or every two years. The youngest...
Dr. Chalasani has a resume of achievements so long that just reading a portion of them took us over a minute! Dr. Chalasani took time out of her busy day to speak with Ann about the state of breast cancer in 2021. She discussed genetics and environmental...
*BioAccel is tax-exempt under §501(c)(3) of the Internal Revenue Code, EIN 26-2751302.The mission of BioAccel is to accelerate the development of new companies and biomedical products by providing entrepreneurs with the needed training, mentoring, and early-stage funding support. Information concerning BioAccel including financial information, its purpose, and its tax returns, may be obtained without cost by writing to our principal place of business at the following address: BioAccel 4602 N 16th Street, Suite 303 Phoenix, AZ 85016, or by calling BioAccel at (602) 385-3210. Your contribution is deductible to the extent permitted by federal law and will help BioAccel meet its mission. Donations solicited and accepted by BioAccel are limited to: Arizona, Idaho, Wyoming, South Dakota, Nebraska, Vermont, and Puerto Rico.
*BioAccel is tax-exempt under §501(c)(3) of the Internal Revenue Code, EIN 26-2751302.The mission of BioAccel is to accelerate the development of new companies and biomedical products by providing entrepreneurs with the needed training, mentoring, and early-stage funding support. Information concerning BioAccel including financial information, its purpose, and its tax returns, may be obtained without cost by writing to our principal place of business at the following address: BioAccel 4602 N 16th Street, Suite 303 Phoenix, AZ 85016, or by calling BioAccel at (602) 385-3210. Your contribution is deductible to the extent permitted by federal law and will help BioAccel meet its mission. Donations solicited and accepted by BioAccel are limited to: Arizona, Idaho, Wyoming, South Dakota, Nebraska, Vermont, and Puerto Rico.
*BioAccel is tax-exempt under §501(c)(3) of the Internal Revenue Code, EIN 26-2751302.The mission of BioAccel is to accelerate the development of new companies and biomedical products by providing entrepreneurs with the needed training, mentoring, and early-stage funding support. Information concerning BioAccel including financial information, its purpose, and its tax returns, may be obtained without cost by writing to our principal place of business at the following address: BioAccel 4602 N 16th Street, Suite 303 Phoenix, AZ 85016, or by calling BioAccel at (602) 385-3210. Your contribution is deductible to the extent permitted by federal law and will help BioAccel meet its mission. Donations solicited and accepted by BioAccel are limited to: Arizona, Idaho, Wyoming, South Dakota, Nebraska, Vermont, and Puerto Rico.
*BioAccel is tax-exempt under §501(c)(3) of the Internal Revenue Code, EIN 26-2751302.The mission of BioAccel is to accelerate the development of new companies and biomedical products by providing entrepreneurs with the needed training, mentoring, and early-stage funding support. Information concerning BioAccel including financial information, its purpose, and its tax returns, may be obtained without cost by writing to our principal place of business at the following address: BioAccel 4602 N 16th Street, Suite 303 Phoenix, AZ 85016, or by calling BioAccel at (602) 385-3210. Your contribution is deductible to the extent permitted by federal law and will help BioAccel meet its mission. Donations solicited and accepted by BioAccel are limited to: Arizona, Idaho, Wyoming, South Dakota, Nebraska, Vermont, and Puerto Rico.
*BioAccel is tax-exempt under §501(c)(3) of the Internal Revenue Code, EIN 26-2751302.The mission of BioAccel is to accelerate the development of new companies and biomedical products by providing entrepreneurs with the needed training, mentoring, and early-stage funding support. Information concerning BioAccel including financial information, its purpose, and its tax returns, may be obtained without cost by writing to our principal place of business at the following address: BioAccel 4602 N 16th Street, Suite 303 Phoenix, AZ 85016, or by calling BioAccel at (602) 385-3210. Your contribution is deductible to the extent permitted by federal law and will help BioAccel meet its mission. Donations solicited and accepted by BioAccel are limited to: Arizona, Idaho, Wyoming, South Dakota, Nebraska, Vermont, and Puerto Rico.
*BioAccel is tax-exempt under §501(c)(3) of the Internal Revenue Code, EIN 26-2751302.The mission of BioAccel is to accelerate the development of new companies and biomedical products by providing entrepreneurs with the needed training, mentoring, and early-stage funding support. Information concerning BioAccel including financial information, its purpose, and its tax returns, may be obtained without cost by writing to our principal place of business at the following address: BioAccel 4602 N 16th Street, Suite 303 Phoenix, AZ 85016, or by calling BioAccel at (602) 385-3210. Your contribution is deductible to the extent permitted by federal law and will help BioAccel meet its mission. Donations solicited and accepted by BioAccel are limited to: Arizona, Idaho, Wyoming, South Dakota, Nebraska, Vermont, and Puerto Rico.